-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

Benzinga·11/17/2026 18:49:33
Listen to the news

On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease.

FDA Approves Oral Breast Cancer Combination Wilserdly

The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

Eligible patients must have an FDA-authorized test detecting the mutation and disease that recurred or progressed after prior endocrine therapy.

Up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations that drive treatment resistance. This all-oral regimen targets two signaling pathways while eliminating the need for injections.

Data from the Phase 3 evERA Breast Cancer study in The New England Journal of Medicine supported the decision.

Following prior CDK4/6 inhibitor therapy, Wilserdly plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus.

Roche also submitted a New Drug Application for Wilserdly as an adjuvant treatment in stage I, II, and III breast cancer based on the Phase 3 lidERA study.

The FDA accepted the filing under Priority Review and set an action date of November 30, 2026, potentially marking the first new adjuvant endocrine therapy in over 20 years.

Gazyva/Gazyvaro Becomes First Approved Primary Membranous Nephropathy Therapy

Separately, the FDA approved Gazyva/Gazyvaro (obinutuzumab) to induce proteinuria remission in adults with primary membranous nephropathy at risk of disease progression.

The agency previously granted the drug Breakthrough Therapy Designation, and it now becomes the first approved treatment for this autoimmune disease that can cause kidney failure.

In the Phase 3 MAJESTY study, 36.1% of adults achieved complete proteinuria remission at 104 weeks versus 5.7% taking tacrolimus, while overall remission reached 50% versus 12.9%. Investigators identified no new safety signals.

This marks the third FDA approval for Gazyva/Gazyvaro in immune-mediated kidney diseases.

The FDA expects to decide on its systemic lupus erythematosus application by December 2026, following a positive recommendation from European regulators.

RHHBY Price Action: Roche Holding shares were down 0.70% at $60.52 at the time of publication on Tuesday. The stock is approaching its 52-week high of $61.75, according to Benzinga Pro data.

Photo by Poetra.RH via Shutterstock